A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial
- PMID: 20698799
- DOI: 10.1089/jop.2009.0145
A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial
Abstract
Purpose: The goals of this study were to compare the efficacy and safety profile of topical cyclosporine 0.05% versus vehicle in Chinese patients with moderate to severe dry eye disease.
Methods: In this multicenter, randomized, double-blind, vehicle-controlled, parallel-group study, 233 dry eye patients were allocated to receive either cyclosporine 0.05% or vehicle twice daily for 8 weeks. Primary outcome was the difference between groups, in total score of 4 symptoms and 4 signs change from baseline at weeks 2, 4, and 8. Changes in symptoms (ocular dryness, foreign body sensation, photophobia and burning) and signs (conjunctival hyperemia, Schirmer test, tear Break-up time (BUT), and corneal punctate fluorescein staining) at weeks 2, 4, and 8 as well as frequency of administration of concomitant artificial tears, were considered as secondary outcomes. The safety profile was evaluated by examining adverse events, changes in visual acuity, and ocular tolerance.
Results: Greater improvements of the total score were seen in cyclosporine 0.05% group than in the vehicle group at all follow-up times (P < 0.01). Improvements in ocular dryness at week 8 (P = 0.040) and foreign body sensation during weeks 4 and 8 (P < 0.020) were significantly greater with cyclosporine. In addition, compared with the vehicle, cyclosporine significantly improved 2 objective dry eye disease signs: corneal staining at weeks 4 (P = 0.025) and 8 (P = 0.050) and the Schirmer test at week 4 (P = 0.035). However, no between-group difference approached statistical significance in photophobia, burning, BUT value, conjunctival hyperemia and frequency of administration of concomitant artificial tears at any follow-up times (P > 0.05).The cumulative frequency of adverse events did not significantly differ between the groups (P = 0.519), which were 11.21% and 8.55%, respectively. There were no patients who experienced reduced visual acuity.
Conclusion: Cyclosporine 0.05% ophthalmic emulsion is an effective and safe treatment for Chinese patients with moderate to severe dry eye disease.
Similar articles
-
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.Ophthalmology. 2000 Apr;107(4):631-9. doi: 10.1016/s0161-6420(99)00176-1. Ophthalmology. 2000. PMID: 10768324 Clinical Trial.
-
Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.Ophthalmology. 2000 May;107(5):967-74. doi: 10.1016/s0161-6420(00)00035-x. Ophthalmology. 2000. PMID: 10811092 Clinical Trial.
-
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.Ophthalmology. 2005 Oct;112(10):1790-4. doi: 10.1016/j.ophtha.2005.05.013. Ophthalmology. 2005. PMID: 16102833 Clinical Trial.
-
Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.J Ocul Pharmacol Ther. 2025 May;41(4):199-209. doi: 10.1089/jop.2024.0169. Epub 2025 Feb 10. J Ocul Pharmacol Ther. 2025. PMID: 39929477
-
Cyclosporine 0.09% solution (Cequa) for dry eye Disease.Med Lett Drugs Ther. 2019 Jul 29;61(1577):116-118. Med Lett Drugs Ther. 2019. PMID: 31381551 Review. No abstract available.
Cited by
-
Management of inflammation in dry eye disease: Recommendations from a European panel of experts.Eur J Ophthalmol. 2023 May;33(3):1294-1307. doi: 10.1177/11206721221141481. Epub 2022 Dec 5. Eur J Ophthalmol. 2023. PMID: 36471573 Free PMC article. Review.
-
Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model.Mol Vis. 2012;18:2195-204. Epub 2012 Aug 8. Mol Vis. 2012. PMID: 22919267 Free PMC article.
-
Dry eye syndrome: developments and lifitegrast in perspective.Clin Ophthalmol. 2018 Jan 15;12:125-139. doi: 10.2147/OPTH.S126668. eCollection 2018. Clin Ophthalmol. 2018. PMID: 29391773 Free PMC article. Review.
-
The Effect of Anti-Inflammatory Topical Ophthalmic Treatments on In Vitro Corneal Epithelial Cells.Transl Vis Sci Technol. 2022 Sep 1;11(9):16. doi: 10.1167/tvst.11.9.16. Transl Vis Sci Technol. 2022. PMID: 36129699 Free PMC article.
-
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.BMC Ophthalmol. 2019 Jun 17;19(1):131. doi: 10.1186/s12886-019-1136-8. BMC Ophthalmol. 2019. Retraction in: BMC Ophthalmol. 2020 Jun 23;20(1):251. doi: 10.1186/s12886-020-01524-8. PMID: 31208393 Free PMC article. Retracted. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical